By: Benzinga
U.S. FDA Approves Alexza's ADASUVE for the Acute Treatment of Agitation Associated with Schizophrenia
Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today that the U.S. Food and Drug Administration (FDA) approved ADASUVE^® (loxapine) Inhalation Powder 10 mg for the acute treatment of agitation associated with schizophrenia or bipolar I disorder in adults. ADASUVE combines Alexza's proprietary Staccato^® delivery system with the antipsychotic drug, loxapine. The Staccato system is
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here